More than 600,000 prescriptions have been issued for oral semaglutide weight loss drug; Novo Nordisk CEO says weight loss drug market has only scratched the surface

Golden Ten Data April 6｜According to the latest disclosed data from Novo Nordisk, prescriptions for its oral weight loss drug semaglutide currently exceed 600,000. UBS estimates that the combined revenue of Eli Lilly’s oral weight loss drug and Novo Nordisk’s oral version of semaglutide will reach approximately 5 billion USD in 2026. However, in the view of Novo Nordisk’s CEO, the weight loss drug market is vast, and the pharmaceutical industry has only scratched the surface. He stated that, including Novo Nordisk, Eli Lilly, and several U.S. producers of compound weight loss drugs, the current supply of weight loss medications can meet only 10% to 15% of the demand among obesity patients.